Interaction between CD40 on B cells and CD40 ligand molecules on T cells is Two antigen nonspecific ligand receptor systems have been distinguished that mediate efficient activation of T and B cells. The first system is characterized by the interactions of CD28 and CTLA-4 on T cells with their physiological counter receptors, the B7 molecules, expressed on B cells and other antigen presenting cells (reviewed in ref. 1). CD28 is found both on resting and activated T cells, while CTLA-4 is expressed only after successful stimulation of T cells (2). The B7 family of receptors consists at present of two cloned molecules, B7.1 and B7.2, and a putative third member, B7.3 (3). Although crosslinking of CD28 alone does not deliver an activation signal to resting T cells, stimulation of preactivated T cells with anti-CD28 monoclonal antibodies (mAb) results in a vigorous proliferative response and marked secretion of multiple lymphokines (1). Conversely, prevention of signaling through CD28 in a cognate T-B cell interaction using Fab fragments of an anti-CD28 antibody results in abrogation of antigen-specific proliferation and in failure to respond to a subsequent antigenic challenge (4, 5).
mice immunized with CD40-1-B cells become tolerant to allogeneic major histocompatibility complex (MHC) antigens as measured by a mixed lymphocyte reaction and cytotoxic T-cell assay. The failure of CD40-'-B cells to serve as antigen presenting cells in vitro was corrected by the addition of anti-CD28 mAb. Moreover, lipopolysaccharide stimulation, which upregulates B7 expression, reversed the inability of CD40--B cells to stimulate an alloresponse in vitro and abrogated the capacity of these B cells to induce tolerance in vivo. These results suggest that CD40 engagement by CD40 ligand expressed on antigen-activated T cells is critical for the upregulation of B7 molecules on antigen-presenting B cells that subsequently deliver the costimulatory signals necessary for T-cell proliferation and differentiation. Our experiments suggest a novel strategy for the induction of antigen-specific tolerance in vivo.
Two antigen nonspecific ligand receptor systems have been distinguished that mediate efficient activation of T and B cells. The first system is characterized by the interactions of CD28 and CTLA-4 on T cells with their physiological counter receptors, the B7 molecules, expressed on B cells and other antigen presenting cells (reviewed in ref. 1) . CD28 is found both on resting and activated T cells, while CTLA-4 is expressed only after successful stimulation of T cells (2) . The B7 family of receptors consists at present of two cloned molecules, B7.1 and B7.2, and a putative third member, B7.3 (3) . Although crosslinking of CD28 alone does not deliver an activation signal to resting T cells, stimulation of preactivated T cells with anti-CD28 monoclonal antibodies (mAb) results in a vigorous proliferative response and marked secretion of multiple lymphokines (1) . Conversely, prevention of signaling through CD28 in a cognate T-B cell interaction using Fab fragments of an anti-CD28 antibody results in abrogation of antigen-specific proliferation and in failure to respond to a subsequent antigenic challenge (4, 5) .
The second receptor ligand system important for lymphocyte activation involves the binding of the B-cell antigen CD40 to its physiological ligand, CD40 ligand (CD40L) expressed on activated T cells. Ligation of CD40 on B cells mediates a wide range of biological activities including homotypic adhesion, proliferation, expression of costimulatory molecules B7.1 and B7.2, and Ig isotype switching (6) (7) (8) (9) . CD40L is transiently expressed predominantly on CD4+ T cells after T-cell receptor (TCR) triggering and independently of CD28/CTLA-4 costimulation (7, 10) .
The capacity of B cells to provide ligands for T-cell specific costimulatory molecules determines the outcome of T-cell activation. Resting B cells express only limited amounts of costimulatory molecules compared to activated B cells (11) and are thus ineffective as antigen presenting cells (12) . This concept has also been demonstrated in vivo. For instance, monovalent rabbit anti-mouse IgD when presented by small resting B cells rendered mice tolerant to rabbit Ig (13) . Polyclonal activation of antigen presenting B cells (e.g., by crosslinking with divalent rabbit anti-mouse IgD) prevented the induction of tolerance (13) . Injection of resting allogeneic B cells has however failed to induce tolerance to allogeneic major histocompatibility complex (MHC) molecules, the principal T-cell targets in an allogeneic immune response (14) . This may be due to the high frequency of allospecific T (15) . Mutant embryonic stem cells from the Ji line heterozygous for CD40 gene-targeting were used for injection into C57BL/6 blastocysts. Chimeric founder mice were mated with C57BL/6 mice and inbreeding of the heterozygous mice resulted in mice homozygous for the CD40 deficiency. The phenotype of these knockout mice is identical to the one of CD40-/-mice obtained by recombinationactivating gene-2-deficient blastocyst complementation (15 
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Antibodies and Fusion Proteins. Antibodies against the following molecules were obtained from PharMingen: CD3-E (clone 145-2C11), CD8a, CD28 (37.51), CD40L (MR1), B200 (CD45R; RA3-6B2), B7-1 (CD80; 1G10), B7-2 (CD86; GL1). Fig. 4 shows that CD40-'-B cells prestimulated with LPS induced an allogeneic response equivalent to that of wild-type B cells pretreated with LPS. Murine CTLA-4/Ig completely inhibited the MLR induced by LPS activated CD40-/-. Thus, the capacity of LPS to confer costimulatory activity on CD40-/-B cells was most likely due to the induction of B7 expression on these cells further confirming the importance of the B7/CD28/CTLA-4 interaction in T-cell activation.
CD40-1-B Cells Induce Allogeneic Tolerance in Vivo.
Engagement of the TCR in the absence of additional costimulatory signals via CD28/CTLA-4 molecules has been demonstrated to result in antigen-specific nonresponsiveness (18) . We therefore examined whether the lack of CD40-mediated up-B7. 
DISCUSSION
T-cell proliferation and their differentiation to various effector functions results from a combination of an antigen-specific, MHC-restricted first signal via TCR engagement and a second antigen-independent signal mediated by costimulatory surface molecules. In the absence of a second signal, T cells will enter a state of antigen-specific unresponsiveness, termed functional inactivation or clonal anergy (18, 19) . Whereas the importance of the CD28/CTLA-4/B7 system for (allogeneic and xenoge- neic) transplantation could be demonstrated by blocking studies in vitro and in vivo, only limited knowledge has accumulated regarding the sequence of physiological events that result in the upregulation of B7 on APCs.
Resting B cells express low densities of B7.1 and B7.2 and are therefore not competent to serve as APCs. T-cell activation via TCR engagement results in the surface expression of CD40L, a contact-dependent process separate from B7/CD28/ CTLA-4 pairing (10). Conversely, activated T cells induce normal B cells to increased B7 and CD54 (ICAM-1) expression via a process that also requires direct cell-cell contact (6) . The mechanism of B7 induction and thus enhanced B-cell antigen-presenting cell activity is CD40/CD40L dependent since the addition of anti-CD40 mAbs or anti-CD40L to the cognate B/T-cell interactions inhibits significantly the increase in B7 expression (6, 20, 21) . Moreover, in vivo co-administration of allogeneic B cells and anti-CD40L mAbs prevented the induction of an in vitro proliferative and cytotoxic T-cell response further emphasizing the paramount importance of the CD40/CD40L axis for T-cell activation (22) .
In this report we demonstrate that B cells deficient in CD40 expression fail to evoke an allogeneic T-cell response both in vitro and in vivo and significantly diminish allospecific T-cell cytotoxic activity. The presented data: (i) the induction of B7 expression by anti-CD40 mAbs, (ii) the reconstitution of the CD40-/-B-cell antigen-presenting capacity in the presence of anti-CD28 mAbs and by treatment with LPS that induces B7 expression, and (iii) the inhibition by CTLA-4/Ig of the ability of LPS to rescue the alloantigen presenting capacity of CD40-/- B 
